期刊
CELL TRANSPLANTATION
卷 23, 期 4-5, 页码 531-539出版社
SAGE PUBLICATIONS INC
DOI: 10.3727/096368914X678337
关键词
Mannitol; Stem cells; Blood-brain barrier permeability; Neurotrophic factors; Cerebral ischemia; Adult; Neonates
资金
- Department of Neurosurgery and Brain Repair funds
- National Institutes of Health, National Institute of Neurological Disorders and Stroke [1R01NS071956-01]
- Department of Defense [W81XWH-11-1-0634]
- James and Esther King Foundation for Biomedical Research Program
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS071956] Funding Source: NIH RePORTER
Ischemic brain injury in adults and neonates is a significant clinical problem with limited therapeutic interventions. Currently, clinicians have only tPA available for stroke treatment and hypothermia for cerebral palsy. Owing to the lack of treatment options, there is a need for novel treatments such as stem cell therapy. Various stem cells including cells from embryo, fetus, perinatal, and adult tissues have proved effective in preclinical and small clinical trials. However, a limiting factor in the success of these treatments is the delivery of the cells and their by-products (neurotrophic factors) into the injured brain. We have demonstrated that mannitol, a drug with the potential to transiently open the blood-brain barrier and facilitate the entry of stem cells and trophic factors, as a solution to the delivery problem. The combination of stem cell therapy and mannitol may improve therapeutic outcomes in adult stroke and neonatal cerebral palsy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据